Group 1 - The company Changshan Pharmaceutical (300255.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of between 190 million to 285 million yuan [1] - The net loss after deducting non-recurring gains and losses is projected to be between 191 million to 286 million yuan [1]

易明医药公告，预计2025年度净利润为7400万元到1.02亿元，同比增长61.12%～122.08%。报告期内， 公司紧随行业发展方向及政策导向，集中资源大力发展自产产品，不断提升自产产品价值与市场占有 率，实现了核心自有产品米格列醇片的销量增长，带动整体利润提升，为公司的长期稳定发展奠定基 础；非经常性损益主要来源于政府补助及博斯泰业绩承诺方补偿款等。预计非经常性损益对公司净利润 影响金额为4300万元。 ...

Core Viewpoint - The company expects a net loss attributable to shareholders for the fiscal year 2025 to be between 76.24 million and 99.12 million yuan, compared to a loss of 62.67 million yuan in the same period last year [1] Financial Performance - The net loss after deducting non-recurring gains and losses is projected to be between 82.25 million and 107 million yuan, compared to a loss of 66.45 million yuan in the previous year [1] - The decline in performance is primarily attributed to a decrease in both sales volume and price of the main product, sodium acetate injection [1] - Additionally, the subsidiary Sichuan Duori is also reporting losses, contributing to the overall decline [1]

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600276 恒瑞医药 | | 3.33 Z | 5.10% | -2.89 Z | -4.43% | -4421.19万 | -0.68% | | 000963 华东医药 | | 1.15 Z | 16.50% | -7275.41万 | -10.40% | -4271.00万 | -6.10% | | 000813 德展健康 | | 1.02亿 | 50.51% | -6009.16万 | -29.70% | -4212.39万 | -20.82% | | 300436 | 广生堂 | 1.01亿 | 5.29% | -2204.37万 | -1.16% | -7860.17万 | -4.13% | | 688382 益方生物 | | 3813.99万 | 13.10% | -337.73万 | -1.16% | -3476.26万 | -11.94% | | 600 ...

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a projected range for net profit attributable to shareholders between -285 million yuan and -190 million yuan, compared to -249 million yuan in the same period last year [1] Financial Performance - The expected net profit range for 2025 is between -286 million yuan and -191 million yuan, with the previous year's figure being -286 million yuan [1] - The company reported a net profit of -249 million yuan in the same period last year [1] Industry Context - The heparin drug industry is experiencing intensified competition, leading to a decline in revenue from the company's core heparin preparation products [1] - Factors such as centralized procurement and fluctuations in raw material prices are contributing to a low gross margin, which is a primary reason for the company's anticipated losses [1]

赛隆药业公告称，近日收到国府嘉盈《辞任函》，因其审计项目任务繁重、团队部分人员变动，自即日 起辞任公司2025年度财务报表审计机构。公司曾于2026年1月16日公告，股东会同意聘任国府嘉盈担任 该年度审计机构。为保证审计工作正常开展，公司正积极与其他事务所沟通，尽快完成后任聘任。不 过，聘任能否及时完成存在不确定性，若2025年度出现特定情形，公司股票可能终止上市。 ...

Core Viewpoint - Yong'an Pharmaceutical is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 18.19 million and 27.05 million yuan [1] - The estimated net profit after deducting non-recurring gains and losses is expected to be between -2.88 million and -1.55 million yuan [1] Market Conditions - The company's performance is anticipated to decline sharply due to a sluggish market environment [1] - The competition in the taurine market has intensified, leading to a decrease in both the production and sales prices of the company's main product, taurine [1]

Core Viewpoint - Yong'an Pharmaceutical announced an expected decline in net profit attributable to shareholders for 2025, forecasting a range of 18.19 million to 27.05 million yuan, representing a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -2.88 million and -1.55 million yuan, indicating a decline of 105.80% to 110.77% year-on-year [1] - The decline in performance is primarily attributed to a sluggish market and intense competition in the taurine market, leading to a decrease in both the production and sales prices of the main product, taurine [1]

Core Viewpoint - Meihua (603538.SH) announced that its subsidiary, Anhui Meihua Pharmaceutical Chemistry Co., Ltd., has received the "High-tech Enterprise Certificate" from the Anhui Provincial Department of Industry and Information Technology, Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province, valid for three years starting from October 28, 2025 [1] Group 1 - Anhui Meihua's high-tech enterprise recognition is a renewal of its previous certificate, which expired [1]

近日，泰恩康发布公告称，预计2025年度归母净利润为2500万元至3500万元，同比下降67.66%至 76.90%；扣除非经常性损益后的净利润为2700万元至3700万元，同比下降65.11%至74.54%。 公告指出，业绩下降主要是由于核心板块两性健康业务面临激烈市场竞争以及销售收入下滑，同时核心 产品"和胃整肠丸"受到产能不足和进口延迟的影响。此外，持续增加的研发和品牌推广投入导致销售费 用上升，从而压缩了利润空间。 （泰恩康公告） ...